A glossary of circulating cytokines in chronic heart failure

European Journal of Heart Failure

Volumn 3, Issue 5, 2001, Pages 517-526

  Adamopoulos, Stamatis ^a   Parissis, John T ^a   Kremastinos, Dimitrios Th ^a  

^a NONE   (Greece)

Author keywords

Chronic heart failure; Cytokines; Immune activation; Inflammatory factors

Indexed keywords

CYTOKINE; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

CARDIOVASCULAR SYSTEM; CYTOKINE PRODUCTION; HEART FAILURE; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

CHRONIC DISEASE; CYTOKINES; FAS LIGAND PROTEIN; HEART FAILURE, CONGESTIVE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKINS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035740739     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00156-8     Document Type: Review

References (90)

1. Cytokines
2. Proinflammatory cytokines
3. Basic mechanisms in congestive heart failure: Recognizing the role of proinflammatory cytokines
4. The role of cytokines in the failing human heart
5. Endotoxin and tumor necrosis factor challenges in dogs stimulate the cardiovascular profile of human septic shock
6. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
7. Cytokine gene expression in rejecting cardiac allografts
8. Basic mechanisms in heart failure: The cytokine hypothesis
9. How are cytokines activated in heart failure?
10. Mechanisms and models in heart failure: A combinatorial approach
11. Tumor necrosis factor (TNF)
12. The pathophysiology of tumor necrosis factors
13. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium
14. Expression and functional significance of tumor necrosis factor receptors in human myocardium
15. Cytokines and cardiac contractile function
16. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
17. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
18. Tumor necrosis factor-alpha and cardiomyopathy
19. The role of tumor necrosis factor in the pathophysiology of heart failure
20. Tumor necrosis factor in CHF: A double facet cytokine
21. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
22. Regression of left ventricular remodeling in chronic heart failure after treatment with ENBREL (Etanercept, p75 TNF Receptor Fc fusion protein)
23. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
24. Stabilization of functional tumor necrosis factor-α by its soluble TNF receptors
25. Tumor necrosis factor-α and tumor factor receptors in the failing human heart
26. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo
27. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro
28. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis
29. Tumor necrosis factor soluble receptors in patients with various degrees of chronic heart failure
30. The biology of interleukin-6
31. Proinflammatory cytokines levels in patients with depressed left ventricular ejection fraction: A report from the SOLVD study
32. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy
33. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
34. Circulating tumor necrosis factor-alpha. Levels in chronic heart failure: Relation to its soluble receptor II, interleukin-6, and neurohormonal variables
35. Circulating interleukin-6 in severe heart failure
36. Prognostic value of serum cytokines in patients with congestive heart failure
37. Targeted disruption of gp130, a common signal transducer for the interleukin-6 family of cytokines, leads to myocardial and haematological disorders
38. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease of hypertension
39. Clinical relevance of cytokine receptor soluble forms in decompensated advanced heart failure
40. IL-1 signal transduction
41. A urine inhibitor of interleukin 1 activity that blocks ligand binding
42. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease
43. Biologic basis for interleukin-1 in disease
44. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock
45. Immunological disorders in patients with dilated cardiomyopathy with special reference to the production of interleukin-2 and the expression of interleukin-2 receptors in the patients' peripheral blood lymphocytes
46. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives
47. Surface marker studies on activated peripheral blood lymphocytes in idiopathic dilated cardiomyopathy
48. Soluble interleukin-2 receptor in patients with dilated cardiomyopathy
49. Diagnostic and prognostic value of soluble interleukin-2 receptor in the serum of patients with idiopathic or ischemic dilated cardiomyopathy
50. Fas and tumor necrosis factor-receptor-mediated cell death: Similarities and distinctions
51. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure
52. Human transplant coronary artery disease: Pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy
53. Peripartum cardiomyopathy: Analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1
54. The cardiac Fas (APO-1/CD95) receptor/Fas ligand system: Relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes
55. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
56. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure
57. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines
58. Inflammation in acute coronary syndromes
59. Human chemokines: An update
60. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells
61. Elevated circulating levels of C-C chemokines in patients with congestive heart failure
62. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload
63. Chemokines and cardiovascular diseases
64. Chemokines: Leukocyte recruitment and activation cytokines
65. RANTES chemokine expression in cell-mediated transplant rejection of the kidney
66. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo
67. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice
68. Systemic inflammation in patients with heart failure
69. CXC-chemokines, a new group of cytokines in congestive heart failure - Possible role of platelets and monocytes
70. The nature and action of granulocyte-macrophage colony-stimulating factors
71. Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor
72. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor
73. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia
74. Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
75. Involvement of adhesion molecules in human monocyte adhesion and transmigration through endothelial cells in vitro
76. Circulating adhesion molecules in disease
77. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissue
78. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis
79. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure
80. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor-α, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
81. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure
82. More cellular signals for atherogenesis?
83. Nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases
84. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers
85. NF-kappaB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene
86. Reactive oxygen species as mediators of signal transduction in cardiovascular disease
87. Increased activity of nuclear factor-κB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats
88. TNF-α heart failure: The difference between proof of principle and hypothesis testing
89. New insights into the pathophysiological role for cytokines in heart failure